论文部分内容阅读
最近几年来,抗菌剂取得的进展是十分显著的。但随着第三代头孢菌素的广泛使用,又出现了MRSA(甲氧西林耐药性黄色葡萄球菌)等难于对付的耐药菌株。因此,今后抗菌剂的研制趋势,将集中到以增强对葡萄球菌和绿脓杆菌抗菌力为中心的β乳胺上来。目前,日本经口抗菌剂的使用情况是:使用头孢菌素类的约占50%;使用青霉素类的约占12%;使用喹诺酮类的约占25%,其余13%左右使用其他种类的抗菌素。在美国,使用头孢菌素类的约占50%;使用青霉素的约占15%;使用大环内酯类抗菌素的约占110%。在欧洲,使用青霉素的约占50%;使用头孢菌素类的约占10%;使用大环内酯类抗菌素的约占17%。由此可见,日本使用喹诺酮类的比例是相当高
In recent years, the progress made by antibacterial agents is very significant. However, with the extensive use of the third generation cephalosporins, resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) have emerged. Therefore, the future development trend of antibacterial agents, will focus on enhancing the Staphylococcus aureus and Pseudomonas aeruginosa antimicrobial power-centered beta up. At present, the use of oral antibacterial agents in Japan is: about 50% of cephalosporins; about 12% of penicillins; about 25% of quinolones, and about 13% of other antibiotics . In the United States, about 50% of cephalosporins are used; about 15% are penicillin; about 110% are macrolide antibiotics. In Europe, about 50% of penicillins are used; about 10% of cephalosporins are used; and about 17% of macrolide antibiotics are used. This shows that the proportion of quinolones used in Japan is quite high